| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | - |
| Drug | Alemtuzumab |
| Brand | Lemtrada® |
| Indication | For adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features |
| Assessment Process | |
| Rapid review commissioned | 08/11/2013 |
| Rapid review completed | 02/12/2013 |
| Rapid review outcome | Full HTA Assessment Recommended |
| Full submission received from Applicant | 28/01/2014 |
| NCPE assessment completed | 25/06/2014 |
| NCPE assessment outcome | The NCPE recommends reimbursement of alemtuzumab (Lemtrada®). |
